Pelareorep
![ASCO 2023: Oncolytics Unleashes Revolutionary Results: BRACELET-1 Trial Harnesses Inflammatory Phenotype for Metastatic HR+/HER2- Breast Cancer with Pelareorep, Paclitaxel, and Avelumab Combo.](https://pharmtales.com/wp-content/uploads/2023/06/ASCO-2023-Oncolytics-Unleashes-Revolutionary-Results-BRACELET-1-Trial-Harnesses-Inflammatory-Phenotype-for-Metastatic-HRHER2-Breast-Cancer-with-Pelareorep-Paclitaxel-and-Avelumab-Combo.jpg)
ASCO 2023: Oncolytics Unleashes Revolutionary Results for Breast Cancer Immunotherapy
SG Tylor
ABSTRACT NUMBER – 1012 Preclinical studies have demonstrated that the oncolytic reovirus Pelareorep can enhance the tumor microenvironment by promoting ...